Study of Colchicine to Treat and Prevent Recurrent Pericarditis (First Episode) (CORP)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00128414|
Recruitment Status : Completed
First Posted : August 10, 2005
Last Update Posted : February 16, 2011
|Condition or disease||Intervention/treatment||Phase|
|Pericarditis Recurrence||Drug: Colchicine (for 6 months) Drug: Placebo||Phase 3|
Colchicine is safe and effective in the management of recurrent pericarditis after failure of conventional treatment. Preliminary data have shown that it may be effective also in treatment of the first attack of recurrent pericarditis and the prevention of further recurrences.
Comparisons: The study will compare the safety and efficacy of colchicine in the treatment of the first attack of recurrent pericarditis and the secondary prevention of recurrences. Colchicine will be used in addition to conventional treatment.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||120 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Treatment and Prevention of Pericarditis With Colchicine. A Multicenter Double Blind Randomized Trial. The CORP Trial: COlchicine for Recurrent Pericarditis|
|Study Start Date :||August 2005|
|Actual Primary Completion Date :||April 2009|
|Actual Study Completion Date :||October 2010|
Placebo Comparator: Placebo
Tablets identical in colour, shape, and taste were provided in blister packs.
Colchicine 1.0 mg twice daily for the first day followed by a maintenance dose of 0.5 mg twice daily for 6 month in patients ≥70 kg, and halved doses for patients <70 kg or intolerant to the highest dose.
Drug: Colchicine (for 6 months)
colchicine 1.0 mg twice daily for the first day followed by a maintenance dose of 0.5 mg twice daily for 1 month in patients ≥70 kg, and halved doses for patients <70 kg or intolerant to the highest dose.
- Recurrence rate at 18 months
- Symptom persistence at 72 hours, remission rate at 1 week
- Number of recurrences
- Time to recurrence
- Disease-related hospitalization, cardiac tamponade, constrictive pericarditis within the duration of the study
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00128414
|Cardiology Dpt. Ospedale SS Annunziata|
|Savigliano, CN, Italy|
|Internal Medicine Dpt. Ospedali Riuniti|
|Department of Cardiology, San Maurizio Regional Hospital|
|Ospedale di Rivoli|
|Cardiology Department. Maria Vittoria Hospital. ASL3 Torino|
|Torino, Italy, 10141|
|Study Chair:||Rita TRINCHERO, MD||Cardiology Department. Maria Vittoria Hospital. ASL 3 Torino|
|Study Chair:||Massimo Imazio, MD||Cardiology Department. Maria Vittoria Hospital. ASL3 Torino.|
|Principal Investigator:||Massimo Imazio, MD||Cardiology Department. Maria Vittoria Hospital. ASL3 Torino.|